Table 1. Patient characteristics of all intensively treated patients with WBC≥100 G/l.
n = 52 | |||
characteristic | n | % | |
Age (years) | |||
median | 60 | ||
range | 21–79 | ||
Female sex | 30 | 58 | |
ECOG 3/4 | 37 | 84 | |
De novo AML | 42 | 81 | |
First diagnosis | 43 | 83 | |
WBC (G/l) | |||
median | 159 | ||
range | 100–322 | ||
Platelets (G/l) | |||
median | 45 | ||
range | 10–149 | ||
Hemoglobin level (g/dl) | |||
median | 9.5 | ||
range | 5.0–14.9 | ||
LDH level (U/l) n = 46 | |||
median | 996 | ||
range | 444–7387 | ||
BM blasts (%) n = 40 | |||
median | 87 | ||
range | 46–99 | ||
PB blasts (%) n = 47 | |||
median | 84 | ||
range | 14 * –99 |
Patients with hyperleukocytosis had a reduced ECOG performance status and highly elevated WBC, LDH level and blast counts.
Abbreviations: BM blasts; bone marrow blasts; EOCG, Eastern Cooperative Group; LDH, lactase dehydrogenase; PB blasts; blasts in the peripheral blood; WBC, white blood count.
*one patient with an AML M5A showed 14% of myeloblasts in the peripheral blood, not accounting for the 59% of monoblasts in AML M5.